NCT04466618View on ClinicalTrials.gov

Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

April 15, 2021

Primary Completion Date

December 15, 2022

Study Completion Date

December 31, 2022

Conditions
HealthyType 2 Diabetes
Interventions
BIOLOGICAL

Saline

Saline infused during the study

BIOLOGICAL

Exendin-9,39

Exendin-9,39 infused during the study

BIOLOGICAL

Saline + Intralipid/Heparin

Saline infused during acute insulin resistance

BIOLOGICAL

Exendin-9,39 + Intralipid/Heparin

Exendin-9,39 infused during acute insulin resistance

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Adrian Vella

OTHER